Ipilimumab: A novel immunomodulating therapy causing autoimmune hypophysitis: A case report and review

European Journal of Endocrinology

Volumn 167, Issue 1, 2012, Pages 1-5

  Juszczak, Agata ^a   Gupta, Avinash ^a,b   Karavitaki, Niki ^a   Middleton, Mark R ^a,b   Grossman, Ashley B ^a  

^a CHURCHILL HOSPITAL   (United Kingdom)

^b UNIVERSITY OF OXFORD   (United Kingdom)

Author keywords

[No Author keywords available]

Indexed keywords

DEXAMETHASONE; DOCETAXEL; FOLLITROPIN; HYDROCORTISONE; IPILIMUMAB; LEVOTHYROXINE; LUTEINIZING HORMONE; PROLACTIN; SOMATOMEDIN C; TESTOSTERONE; THYROTROPIN; THYROXINE;

ADULT; AUTOIMMUNE DISEASE; AUTOIMMUNE HYPOPHYSITIS; BRAIN EDEMA; CANCER CHEMOTHERAPY; CANCER RELAPSE; CASE REPORT; COMPUTER ASSISTED TOMOGRAPHY; DRUG DOSE REDUCTION; DRUG SUBSTITUTION; DRUG WITHDRAWAL; ERECTILE DYSFUNCTION; FOLLOW UP; HEADACHE; HORMONE SUBSTITUTION; HUMAN; HYPOPHYSITIS; HYPOPITUITARISM; IMMUNOMODULATION; LETHARGY; LIBIDO DISORDER; LUNG METASTASIS; MALE; METASTATIC MELANOMA; NEUROIMAGING; NUCLEAR MAGNETIC RESONANCE IMAGING; PRIORITY JOURNAL; REVIEW;

ANTIBODIES, MONOCLONAL; AUTOIMMUNE DISEASES; CTLA-4 ANTIGEN; HUMANS; HYPOPITUITARISM; MALE; MELANOMA; MIDDLE AGED; SKIN NEOPLASMS; T-LYMPHOCYTES, CYTOTOXIC;

EID: 84862744031     PISSN: 08044643     EISSN: 1479683X     Source Type: Journal    
DOI: 10.1530/EJE-12-0167     Document Type: Review

References (15)

1. Chambers CA, Kuhns MS, Egen JG & Allison JP. CTLA-4-mediated inhibition in regulation of T cell responses: mechanisms and manipulation in tumor immunotherapy. Annual Review of Immunology 2001 19 565-594. (doi:10.1146/annurev.immunol.19.1.565)
2. Hanaizi Z, van Zwieten-Boot B, Calvo G, Lopez AS, van Dartel M, Camarero J, Abadie E & Pignatti F. The European Medicines Agency review of ipilimumab (Yervoy) for the treatment of advanced (unresectable or metastatic) melanoma in adults who have received prior therapy: summary of the scientific assessment of the Committee for Medicinal Products for Human Use. European Journal of Cancer 2012 48 237-242. (doi:10.1016/j.ejca.2011.09.018)
3. Robert C, Thomas L, Bondarenko I, O'Day S, M DJ, Garbe C, Lebbe C, Baurain JF, Testori A, Grob JJ, Davidson N, Richards J, Maio M, Hauschild A, Miller WH Jr, Gascon P, Lotem M, Harmankaya K, Ibrahim R, Francis S, Chen TT, Humphrey R, Hoos A & Wolchok JD. Ipilimumab plus dacarbazine for previously untreated metastatic melanoma. New England Journal of Medicine 2011 364 2517-2526. (doi:10.1056/NEJMoa1104621)
4. Hodi FS, O'Day SJ, McDermott DF, Weber RW, Sosman JA, Haanen JB, Gonzalez R, Robert C, Schadendorf D, Hassel JC, Akerley W, van den Eertwegh AJ, Lutzky J, Lorigan P, Vaubel JM, Linette GP, Hogg D, Ottensmeier CH, Lebbe C, Peschel C, Quirt I, Clark JI, Wolchok JD, Weber JS, Tian J, Yellin MJ, Nichol GM, Hoos A & Urba WJ. Improved survival with ipilimumab in patients with metastatic melanoma. New England Journal of Medicine 2010 363 711-723. (doi:10.1056/ NEJMoa1003466)
5. O'Day SJ, Hamid O & Urba WJ. Targeting cytotoxic T-lymphocyte antigen-4 (CTLA-4): a novel strategy for the treatment of melanoma and other malignancies. Cancer 2007 110 2614-2627. (doi:10.1002/cncr.23086)
6. Weber J. Ipilimumab: controversies in its development, utility and autoimmune adverse events. Cancer Immunology, Immunotherapy 2009 58 823-830. (doi:10.1007/s00262-008-0653-8)
7. Caturegli P, Newschaffer C, Olivi A, Pomper MG, Burger PC & Rose NR. Autoimmune hypophysitis. Endocrine Reviews 2005 26 599-614. (doi:10.1210/er. 2004-0011)
8. Min L, Vaidya A & Becker C. Ipilimumab therapy for advanced melanoma is associated with secondary adrenal insufficiency: a case series. Endocrine Practice 2011 1-13. (doi:10.4158/EP11273.OR)
9. Maker AV, Yang JC, Sherry RM, Topalian SL, Kammula US, Royal RE, Hughes M, Yellin MJ, Haworth LR, Levy C, Allen T, Mavroukakis SA, Attia P & Rosenberg SA. Intrapatient dose escalation of anti-CTLA-4 antibody in patients with metastatic melanoma. Journal of Immunotherapy 2006 29 455-463. (doi:10.1097/01.cji.0000208259.73167.58)
10. Downey SG, Klapper JA, Smith FO, Yang JC, Sherry RM, Royal RE, Kammula US, Hughes MS, Allen TE, Levy CL, Yellin M, Nichol G, White DE, Steinberg SM & Rosenberg SA. Prognostic factors related to clinical response in patients with metastatic melanoma treated by CTL-associated antigen-4 blockade. Clinical Cancer Research 2007 13 6681-6688. (doi:10.1158/1078-0432.CCR-07-0187)
11. Dillard T, Yedinak CG, Alumkal J & Fleseriu M. Anti-CTLA-4 antibody therapy associated autoimmune hypophysitis: serious immune related adverse events across a spectrum of cancer subtypes. Pituitary 2010 13 29-38. (doi:10.1007/s11102-009-0193-z)
12. Blansfield JA, Beck KE, Tran K, Yang JC, Hughes MS, Kammula US, Royal RE, Topalian SL, Haworth LR, Levy C, Rosenberg SA & Sherry RM. Cytotoxic T-lymphocyte-associated antigen-4 blockage can induce autoimmune hypophysitis in patients with metastatic melanoma and renal cancer. Journal of Immunotherapy 2005 28 593-598. (doi:10.1097/01.cji.0000178913.41256.06)
13. Barnard ZR, Walcott BP, Kahle KT, Nahed BV & Coumans JV. Hyponatremia associated with ipilimumab-induced hypophysitis. Medical Oncology 2012 29 374-377. (doi:10.1007/s12032-010-9794-7)
14. Carpenter KJ, Murtagh RD, Lilienfeld H, Weber J & Murtagh FR. Ipilimumab-induced hypophysitis: MR imaging findings. AJNR. American Journal of Neuroradiology 2009 30 1751-1753. (doi:10.3174/ajnr.A1623)
15. Phan GQ, Yang JC, Sherry RM, Hwu P, Topalian SL, Schwartzentruber DJ, Restifo NP, Haworth LR, Seipp CA, Freezer LJ, Morton KE, Mavroukakis SA, Duray PH, Steinberg SM, Allison JP, Davis TA & Rosenberg SA. Cancer regression and autoimmunity induced by cytotoxic T lymphocyte-associated antigen 4 blockade in patients with metastatic melanoma. PNAS 2003 100 8372-8377. (doi:10.1073/pnas.1533209100)